Keywords: Johnson & Johnson, Zytiga, Prostate cancer, Dendreon, Provenge, Decision Resources

Johnson & Johnson’s Zytiga set to earn peak sales of $910 million for metastatic castrate-resistant prostate cancer; study

Article | 06 June 2011

Print This

US health care giant Johnson & Johnson’s (NYSE: JNJ) Zytiga (abiraterone acetate) will earn peak year sales of $910 ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in